BRIEF—Bionure appoints new chief medical officer

Neuroprotection specialist Bionure has appointed Lucia Septien as chief medical officer. Dr Septien previously held senior medical and regulatory roles at firms including Pfizer and GlaxoSmithKline, before becoming CMO at DBV Technologies.

Bionure is gearing up for a Phase II clinical study of its lead compound, BN201, following a successful Phase I study that demonstrated neuroprotective activity and stimulation for remyelination.

The company, which is based in Barcelona, Spain, is primarily focused on developing therapies for acute optic neuritis and multiple sclerosis.